We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 218.00
Bid: 215.00
Ask: 217.50
Change: 5.50 (2.59%)
Spread: 2.50 (1.163%)
Open: 219.50
High: 219.50
Low: 207.00
Prev. Close: 212.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

10 Mar 2020 07:00

RNS Number : 5158F
PureTech Health PLC
10 March 2020
 

10 March 2020

PureTech Health plc

 

Notice of Results

 

PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company") plans to announce its financial results for the year ended 31 December 2019 on Thursday, 9 April 2020.

 

A presentation and conference call for analysts will take place at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will be available on the Company's website at http://puretechhealth.com/investors under the Reports and Presentations tab.

 

PureTech also confirms that the global outbreak of COVID-19 has not adversely affected the Company's business of addressing major diseases through its leadership in immunology and the Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash position and is advancing the business in accordance with its previously announced strategy and timelines while continuing to monitor the situation.

 

About PureTech Health

PureTech is a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBCGDXUXGDGGC
Date   Source Headline
23rd Mar 20237:00 amRNSPRTC Gets Up To $500M From RPRX For KarXT Royalty
23rd Mar 20237:00 amRNSTransaction in Own Shares
22nd Mar 20231:10 pmRNSTransaction in Own Shares
21st Mar 20237:00 amRNSTransaction in Own Shares
20th Mar 202311:42 amRNSKaruna 2nd Successful Ph3 Study in Schizophrenia
20th Mar 20237:00 amRNSTransaction in Own Shares
17th Mar 20237:00 amRNSTransaction in Own Shares
16th Mar 20237:00 amRNSTransaction in Own Shares
15th Mar 20237:00 amRNSTransaction in Own Shares
14th Mar 20237:00 amRNSTransaction in Own Shares
13th Mar 20237:00 amRNSTransaction in Own Shares
10th Mar 20237:00 amRNSTransaction in Own Shares
9th Mar 20237:00 amRNSTransaction in Own Shares
8th Mar 20237:00 amRNSTransaction in Own Shares
7th Mar 20237:00 amRNSTransaction in Own Shares
6th Mar 20237:00 amRNSTransaction in Own Shares
3rd Mar 20237:00 amRNSTransaction in Own Shares
2nd Mar 20237:00 amRNSTransaction in Own Shares
1st Mar 202312:00 pmRNSPureTech to Present at Barclays Healthcare Conf
1st Mar 20237:00 amRNSTransaction in Own Shares
28th Feb 20237:00 amRNSTransaction in Own Shares
27th Feb 20232:09 pmRNSSonde & MGH Lead Study on Frontotemporal Disorders
27th Feb 20237:00 amRNSTransaction in Own Shares
24th Feb 20237:00 amRNSTransaction in Own Shares
23rd Feb 20237:00 amRNSTransaction in Own Shares
22nd Feb 20237:00 amRNSTransaction in Own Shares
21st Feb 20237:00 amRNSTransaction in Own Shares
20th Feb 20237:00 amRNSTransaction in Own Shares
17th Feb 20235:00 pmRNSDirector/PDMR Shareholding
17th Feb 20237:00 amRNSTransaction in Own Shares
16th Feb 20237:00 amRNSTransaction in Own Shares
15th Feb 20237:00 amRNSTransaction in Own Shares
14th Feb 202312:00 pmRNSPRTC Plans Ph2a trials w/ LYT-300 in PPD/Anxiety
14th Feb 20237:00 amRNSTransaction in Own Shares
13th Feb 20237:00 amRNSTransaction in Own Shares
10th Feb 20237:00 amRNSTransaction in Own Shares
9th Feb 20237:00 amRNSTransaction in Own Shares
8th Feb 20237:00 amRNSTransaction in Own Shares
7th Feb 20237:00 amRNSTransaction in Own Shares
6th Feb 20237:00 amRNSTransaction in Own Shares
3rd Feb 20237:00 amRNSTransaction in Own Shares
2nd Feb 20237:00 amRNSTransaction in Own Shares
1st Feb 202312:00 pmRNSPureTech to Present at SVB Global Biopharma Conf.
1st Feb 20237:00 amRNSTotal Voting Rights
1st Feb 20237:00 amRNSTransaction in Own Shares
31st Jan 20237:00 amRNSTransaction in Own Shares
30th Jan 20237:00 amRNSTransaction in Own Shares
27th Jan 20237:00 amRNSTransaction in Own Shares
25th Jan 20237:00 amRNSTransaction in Own Shares
6th Jan 20237:00 amRNSAKLI Positive ADHD Pivotal Data in Kids 13-17 yrs

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.